See What HealthDay Can Do For You
Contact Us

Hormone Antagonist, Chemo May Reduce Breast Tumors

Combination cuts tumor volume by over 97 percent in laboratory animals

TUESDAY, Jan. 30 (HealthDay News) -- A combination of treatments including chemotherapy and an inhibitor of the growth hormone-releasing hormone (GHRH) may be effective in reducing or eliminating breast tumors, according to the results of a study in animals published online Jan. 29 in the Proceedings of the National Academy of Sciences Early Edition.

Stefan Buchholz, of Tulane University School of Medicine in New Orleans, and colleagues tested the effectiveness of the GHRH antagonist JMR-132, either alone or in combination with docetaxel therapy, on the growth of human breast tumors in nude mice.

While 10 micrograms of JMR-132 per day for three weeks reduced tumor volume by 63 percent, this dose in combination with docetaxel further reduced tumor volume by greater than 97 percent. No toxicity or other major side effects from the treatment were noted.

"Our results demonstrate that GHRH antagonists might provide a therapy for breast cancer and could be combined with docetaxel chemotherapy to enhance the efficacy of treatment," the authors conclude.

Two of the study authors are co-inventors on a patent application for JMR-132 submitted by Tulane University.

Full Text (subscription or payment may be required)

Physician's Briefing